ONEBIO

AdBio partners (formerly Advent France Biotechnology) is a venture capital firm investing in early stage life sciences companies in Europe. AdBio partners’ unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company’s growth. As an early-stage investor, we act as a catalyst to create companies based on innovations coming from academic research. We have established relationships with leading research institutions and technology transfer offices in Europe and benefit from the support of strong network of scientific, clinical, industry and financial partners. The operational team is managed by Alain Huriez, MD, Chairman and Managing Partner, and Geoffroy de Ribains, Managing Partner. The team includes seasoned investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific, medical and operational expertise.

We use our domain expertise, network, and prior experiences to help our founders scale commercialization, product, and engineering. Post-science project investing We recognize that starting and building a company is hard. Startups by definition are outliers being built by unique collections of humans. We utilize our deep domain expertise to uniquely understand the problems of companies in the categories we care about. Pairing this with our experience working with deep technology, allows us to provide leverage in taking a company from pre, to post-commercialization and building engineering teams across both research and production-level eng.

We support the development of novel medicines that address significant unmet medical needs. As co-investors, you will find us straight forward, transparent, long term oriented and asking “is this the right thing to do for the company” at every step of our decision making. Investment strategy and approach Our investment and portfolio construction strategy builds on lessons learned and approaches perfected during the 15 years the founding team worked together. We invest in companies that are about to enter the most value-generating phase of drug development i.e. clinical stage. Our capital helps answer the question “Is there a drug that works here?” We can lead, co-lead or follow. We (almost) always take Board seats in companies we invest in and lay particular emphasis on aligning our investment objectives to fellow investors’ investment interests. We always reserve capital for future capital raises and do not do investments in which we cannot. We invest in companies where it is possible for a private investor or venture syndicate to finance the R&D program all the way to regulatory approval. Therapeutic area focus All modalities and therapeutic areas are in scope as long as the biotech company is developing a novel medicine. Out of scope are investments that are, in our judgment, incremental innovation or a pureplay regulatory or pricing story. Medical devices, digital health and diagnostics companies are out of scope. Stage of company We invest in about-to-be clinical and clinical stage companies where the investment will result in a clinical readout for the lead asset. We can invest in any private financing round irrespective of whether its termed Series A, B, C or Cross-over Platform companies are also attractive, as long as the lead asset will get to a clinical readout with the financing. Geographic footprint We invest in companies in Europe and United States. We lay particular emphasis in investing in companies with Scandinavian roots, like our Firm has, and often start and build companies in Swedish and Danish ecosystem. Diseases afflicting people does not recognize geographic boundaries, science is global, financial capital is globally distributed and human capital is globally mobile. Therefore, we believe companies need to be built with that global perspective in mind. Our Core Values DECENT We show respect at all times We act with integrity and always aim to do the right thing Being reasonable builds long-term relationships DEDICATED We work hard to deliver results for patients, our companies and our LPs We are highly professional We love what we do CONFIDENT Our combined experience is extensive – we have been there before We trust our capabilities We are supported by a strong and extensive network HUMBLE We know our limitations We know when to listen and when to ask questions We are responsible stewards of our LP’s capital

Since its genesis at the University of Oxford in 2015, Panacea Innovation has partnered with some of the world’s best sci-entrepreneurs, research bodies, universities and corporates to build more than 280 companies that offer cutting-edge solutions - curating a portfolio of more than GBP£300m in value. Panacea Innovation’s venturing activities are delivered through two complementary arms: Panacea Stars - a technology translation, commercialisation and R&D arm - and Panacea Ventures, the investment management one.

We invest in opportunities backed by deep science. Xora is an early-stage investment platform of Temasek. We typically invest as a lead or co-lead investor in the Seed and Series A rounds, and later rounds (via our parent company). While we are not limited by geography, we prioritize opportunities that possess a strong linkage with the Singapore science & technology ecosystem. Leveraging the Temasek global network of investors and operating companies, we are active partners to ambitious founders building the next generation of impactful, world-changing companies. Our Team Our team possesses strong technical domain expertise in both physical and life sciences, and the intersection thereof, and are steeped in the nuances of early-stage deep science investing and venture building. We are global citizens with business experience in major markets. Our principles guide our engagement process and our investment decisions.We start with the people on the journey and a shared vision of the future. ​ We look for dogged persistence, unbounded creativity, acute self-awareness, a sense of urgency, and a passion for impact. We embrace both the technical and people complexity of science-based opportunities. ​ We welcome early and frequent contact and appreciate the opportunity to inform an emerging narrative. ​ We prefer brainstorming to pitches, and relationships to transactions. ​ We commit more than capital; we pledge our mindshare and our network.

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our team is made up of life science experts and business analysts that can guide life science companies’ development throughout the entire research and development process. BioGeneration Ventures leverages its knowledge gained from working with a diverse network. This includes universities, early stage biotech companies and large pharma. We enable a range of sector-relevant expertise to build and accelerate product development and transform entrepreneurs and their companies to become attractive investment opportunities within the life sciences industry. Our Strategy BioGeneration Ventures (BGV) was launched in 2006. We manage over EUR 250 million across four funds. BGV invests in medical and healthcare innovations that have high potential to positively impact patients. BGV works with an ethos founded in sound novel science. We seek those innovations that have a truly differentiated scientific basis, supported by convincing experimental data. These innovations must be compelling and stand out in the global scientific arena. Only innovations that can address a significant unmet medical need are considered for investment. We aspire to invest in solutions that provide substantial healthcare impact. Progressing a project from discovery to clinical proof-of-concept requires a breadth of experience that founding teams usually do not have from the outset. Through our extensive network and experience we help founders build their companies to extend their capabilities. We guide our portfolio companies along their journey from the scientific discovery to a targeted product development track. Together with the founders, we seeks to shape the companies and define the objectives that enable a successful exit. Our partnerships BGV invests in partnerships with other professional investors in life sciences and has built relationships with various academic institutions (such as Leiden University), venture capital investors in the Netherlands, the EU and the US. Forbion: BGV operates a joint venture partnership with Forbion, a leading European life sciences venture capital fund. Mibiton: Mibiton provides loans to enable promising young life sciences companies to purchase equipment. BGV actively supports the investment activities with BGV Managing Partner Edward van Wezel serving as a member of the board. Our Investors: BGV has a broad investor base comprising private equity/wealth managers, pension funds, academic institutions, regional development funds and private investors.